MESTINON SUMMARY
VALENANT Pharmaceuticals International MESTINON® (pyridostigmine bromide tablets, USP) SYRUP TABLETS and TIMESPAN® TABLETS
Mestinon (pyridostigmine bromide tablets, USP) is an orally active cholinesterase inhibitor.
Mestinon (pyridostigmine cation) is indicated for the following:
Mestinon is useful in the treatment of myasthenia gravis.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Mestinon (Pyridostigmine)
Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. [2010.11] Orthostatic hypotension affects patients with autonomic failure producing considerable disability because of presyncopal symptoms. Severely affected patients may have residual sympathetic tone that can be engaged to increase blood pressure (BP) with the alpha-2 adrenergic antagonist yohimbine.Engaging residual sympathetic tone with yohimbine is a more effective approach to improve orthostatic hypotension as compared with pyridostigmine in patients with severe orthostatic hypotension.
Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. [2009.08] HIV infection is characterized by persistent immune activation, increased production of proinflammatory cytokines, and rapid T cell turnover...
Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. [2009.07] 3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination... Therefore, we performed a placebo-controlled, double-dummy, double-blind, randomized, crossover study in nine patients with LEMS.
The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. [2009.03] BACKGROUND: There is limited information on medications with promotility effects on the esophagus. Studies in healthy volunteers have shown the potential role of the direct cholinergic agonist bethanechol and the serotonin receptor agonist buspirone in improving esophageal motility. It has been also shown that an acetylcholinesterase inhibitor, the short-acting drug edrophonium administered intravenously caused a greater increase in the esophageal contraction amplitude and duration than bethanechol. Edrophonium cannot be used as a promotility therapy owing to short duration of action and lack of oral administration. The use of another acetylcholinesterase inhibitor pyridostygmine with longer duration of action has not been studied. The aim of the study was to evaluate the effect of oral pyridostygmine (60 mg), buspirone (20 mg), and bethanechol (25 mg) on esophageal function assessed by combined multichannel intraluminal impedance-esophageal manometry... CONCLUSIONS: Oral pyridostygmine, buspirone, and bethanechol enhance esophageal motility with pyridostygmine appearing to have the greatest effect. A potential effect on improving esophageal function and symptoms in patients requires further study.
A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. [2008.02] OBJECTIVE: A subset of fibromyalgia (FM) patients have a dysfunctional hypothalamic-pituitary-insulin-like growth factor 1 (IGF-1) axis, as evidenced by low serum levels of IGF-1 and a reduced growth hormone (GH) response to physiologic stimuli. There is evidence that pyridostigmine (PYD) improves the acute response of GH to exercise in FM patients. The purpose of this study was to evaluate the clinical effectiveness of 6 months of PYD and group exercise on FM symptoms... CONCLUSION: Neither the combination of PYD plus supervised exercise nor either treatment alone yielded improvement in most FM symptoms. However, PYD did improve anxiety and sleep, and exercise improved fatigue and fitness. We speculate that PYD may have improved vagal tone, thus benefiting sleep and anxiety; this notion warrants further study.
Clinical Trials Related to Mestinon (Pyridostigmine)
A Pilot Study of Pyridostigmine in Pompe Disease [Not yet recruiting]
Pyridostigmine is an acetylcholinesterase inhibitor, which degrades acetylcholine at the
neuromuscular junction. Based on recent studies, pyridostigmine may be an effective adjuvant
treatment for people with Pompe disease, as it increases the functional impact of this
neurotransmitter.
Hypothesis: the use of pyridostigmine in Pompe disease will improve transmission of
acetylcholine across the neuromuscular junction, skeletal muscle function, respiratory
function, and quality of life.
Use of Pyridostigmine for Constipation in Diabetics [Completed]
Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the
speed at which food travels through the stomach, intestines and colon, and if pyridostigmine
improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved
by the Food and Drug Administration (FDA) for routine clinical use, however, its use as
proposed in this study is considered investigational.
Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment [Recruiting]
Disabling symptoms of blood pressure dysregulation, impaired swallowing and digestion are
common amongst Parkinson`s patients. So far the exact pathophysiology for this is not fully
understood. There are results from pathological analyses that the autonomic nervous system
is also affected by the accumulation of alpha-Synuclein and that this might even happen in
very early stages of the disease process (Qualman et al., 1984; Wakabayashi et al., 1989;
Wakabayashi et al., 1990; Bloch et al., 2006).
Blood pressure dysregulation is a common autonomic symptom in Parkinson`s patients and
treatment - currently most often achieved with Fludrocortisone - often leads to supine
hypertension (Plaschke et al., 1998; Braune et al., 1999; Magerkurth et al., 2005).
There are studies in patients with autonomic failure that indicate that Pyridostigmine
bromide might be an alternative treatment option without causing disabling supine
hypertension (Singer et al., 2003; Sandroni et al., 2005; Singer et al., 2006; Yamamoto et
al., 2006).
Delayed gastric emptying is also an autonomic symptom associated with Parkinson`s disease.
By the elevation of the cholinergic tone with Pyridostigmine bromide the investigators also
expect to alleviate symptoms of delayed gastric emptying and obstipation, possibly even
facilitating the uptake of dopaminergic medication through the gut (Sadjadpour, 1983;
Bharucha et al., 2008).
Therefore the investigators designed a monocentric randomized, controlled, double blind,
crossover phase II trial to show non-inferiority of the effect of pyridostigmine bromide vs.
fludrocortisone on symptoms of autonomic dysregulation in Parkinson`s disease.
Testing Mestinon and Exercise in Fibromyalgia [Completed]
The purpose of this trial was to test the combined and independent effects of 6 months of
exercise and Mestinon in people with fibromyalgia. Specifically, we wanted to determine if
Mestinon helped people with fibromyalgia have an easier time exercising and if their
symptoms improved by the end of the trial.
The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine [Recruiting]
Pyridostigmine is a medication that is used in certain heart rate and blood pressure
conditions. This medication, as a side effect, is known to also cause changes in the
junction between a nerve and muscle. The changes caused at the nerve muscle junction by
pyridostigmine could alter the effect of muscle relaxants (a medication used during surgery
and anesthesia). The investigators are conducting this study to see whether patients taking
pyridostigmine are more or less sensitive to rocuronium (a muscle relaxing medication used
during surgery).
Reports of Suspected Mestinon (Pyridostigmine) Side Effects
Dysphagia (5),
Cerebrovascular Accident (3),
Infection (2),
Malaise (2),
Diarrhoea (2),
Myasthenia Gravis (1),
Drug Interaction (1),
Drug Label Confusion (1),
Medication Error (1),
Dizziness (1), more >>
|
|
Page last updated: 2011-12-09
|